Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18327756 | 0.87 | HTR2C (0.41) | EGFRNQO2HTR6ANO1ESR2 | |
| SCHEMBL6675964 | 0.84 | HTR2A (0.40) | GRM2 | |
| SCHEMBL1844754 | 0.82 | CYP3A4 (0.39) | — | |
| SCHEMBL6674892 | 0.80 | MEN1 (0.44) | HSD17B10 | |
| SCHEMBL12578338 | 0.78 | KDM4E (0.40) | — | |
| SCHEMBL6678438 | 0.78 | GRM2 (0.35) | GRM2 | |
| SCHEMBL19794855 | 0.77 | STK17B (0.38) | GRM2 | |
| SCHEMBL12578615 | 0.77 | SLC6A2 (0.35) | GRM2 | |
| SCHEMBL507755 | 0.77 | PYCR1 (0.45) | — | |
| SCHEMBL6678436 | 0.77 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | EGFR 1793/4885NQO2 2766/4885HTR6 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.